MDT

96.14

-0.57%↓

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

Начало・Списък с акции・Simulations Plus Inc

Simulations Plus Inc

Затворен

СекторЗдравеопазване

18.19 0.33

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

17.93

Максимум

18.27

Ключови измерители
By Trading Economics
Приходи	67M -681K
Продажби	-2.9M 17M
P/E Средно за сектора	48.528 88.032
EPS	-0.034
Дивидентна доходност	0.48
Марж на печалбата	-3.9
Служители	212
EBITDA	327K 5.3M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+12.21% upside

Дивиденти
By Dow Jones
Дивидентна доходност Средно за сектора	0.48% 2.26%
Следващи печалби	8.01.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	24M 368M
Предишно отваряне	17.86
Предишно затваряне	18.19

Настроения в новините

By Acuity

50%

157 / 374 Класиране в Healthcare

Simulations Plus Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

31.12.2025 г., 22:20 ч. UTC

Значими двигатели на пазара

Outlook Therapeutics Shares Fall After Another FDA Rejection of Macular Degeneration Drug

31.12.2025 г., 17:31 ч. UTC

Значими двигатели на пазара

OwlTing Climbs on Launch of $10 Million Stock-Buyback Program

31.12.2025 г., 16:30 ч. UTC

Значими двигатели на пазара

Trump Media Gains on Plan to Distribute Digital Tokens to Shareholders

31.12.2025 г., 15:19 ч. UTC

Значими двигатели на пазара

Axsome Shares Climb on FDA Fast‑Track for Alzheimer's Drug, Backing for Narcolepsy Filing

31.12.2025 г., 15:17 ч. UTC

Значими двигатели на пазара

Nike Shares Rise After CEO Hill Buys $1 Million of Shares

31.12.2025 г., 14:37 ч. UTC

Значими двигатели на пазара

Corcept Shares Fall as FDA Requires More Evidence for Hypercortisolism Drug Application

31.12.2025 г., 21:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

31.12.2025 г., 21:13 ч. UTC

Придобивния, сливания и поглъщания

10 People to Watch in Wealth Management in 2026 -- Barrons.com

31.12.2025 г., 20:40 ч. UTC

Пазарно говорене

Dollar Posting Its Worst Year Since 2017 -- Market Talk

31.12.2025 г., 20:22 ч. UTC

Пазарно говорене

Oil Posts Loss in a Year Marked By Plentiful Supply -- Market Talk

31.12.2025 г., 19:50 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Sink on Weather Outlook -- Market Talk

31.12.2025 г., 19:31 ч. UTC

Пазарно говорене

Precious Metals Cap Off Record Runs -- Market Talk

31.12.2025 г., 18:50 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

31.12.2025 г., 18:50 ч. UTC

Пазарно говорене

Canadian Gold Miners Enjoy a Bumper Year in 2025 -- Market Talk

31.12.2025 г., 17:17 ч. UTC

Пазарно говорене

U.S. Natural Gas Inventories Fall Less Than Expected -- Market Talk

31.12.2025 г., 17:16 ч. UTC

Значими двигатели на пазара

OwlTing Climbs on Launch of $10M Stock-Buyback Program

31.12.2025 г., 17:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

31.12.2025 г., 17:00 ч. UTC

Придобивния, сливания и поглъщания

Nvidia Is Getting Creative as Options to Use Its Cash Flood Narrow -- Heard on the Street -- WSJ

31.12.2025 г., 15:57 ч. UTC

Придобивния, сливания и поглъщания

Vanda Pharmaceuticals Shares Jump 30% on Motion Sickness Drug Approval -- Barrons.com

31.12.2025 г., 15:54 ч. UTC

Пазарно говорене

Layoff Data Supports Dollar at End of Losing Year -- Market Talk

31.12.2025 г., 15:02 ч. UTC

Значими двигатели на пазара

Nike Shares Rise After CEO Hill Buys $1M of Shares

31.12.2025 г., 14:40 ч. UTC

Придобивния, сливания и поглъщания

Nike CEO Buys $1 Million of Stock as Insiders Bet on a Turnaround -- Barrons.com

31.12.2025 г., 14:20 ч. UTC

Пазарно говорене

Crude Futures On Track to End the Year With Losses -- Market Talk

31.12.2025 г., 13:46 ч. UTC

Пазарно говорене

U.S. Natural Gas Falls on Milder Weather Outlook -- Market Talk

31.12.2025 г., 13:01 ч. UTC

Печалби

Придобивния, сливания и поглъщания

Charles Schwab Is Back on Offense. Its Stock Is a Buy. -- Barrons.com

31.12.2025 г., 11:10 ч. UTC

Пазарно говорене

Copper Remains in Touching Distance of Record Highs -- Market Talk

31.12.2025 г., 10:46 ч. UTC

Пазарно говорене

Euro on Track For Strong Annual Performance -- Market Talk

31.12.2025 г., 10:25 ч. UTC

Пазарно говорене

European Gas Prices Rise But Remain on Track for Heavy Annual Loss -- Market Talk

31.12.2025 г., 10:23 ч. UTC

Пазарно говорене

Chinese Yuan Rises to 31-Month High Against Dollar as Policymakers -- Market Talk

31.12.2025 г., 09:33 ч. UTC

Пазарно говорене

Dollar Set For Worst Annual Performance Since 2017 -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Simulations Plus Inc Прогноза

Ценова цел

By TipRanks

12.21% нагоре

12-месечна прогноза

Среден 20.5 USD 12.21%

Висок 25 USD

Нисък 16 USD

Според 5 анализатори от Wall Street, предложили 12-месечна ценова цел за Simulations Plus Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

5 ratings

Купи

Задържане

Продай

Според 5 анализатори, дали борсови рейтинги на Simulations Plus Inc през последните 3 месеца.

Настроение

By Acuity

157 / 374 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.